Developer docs
API playgroundTry for free, no card

Search company profiles

Resolution Therapeutics

Full company profile

uuid000051b

Namestring
Resolution Therapeutics
Legal namestring
Resolution Therapeutics Limited
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Resolution Therapeutics Limited is a clinical-stage biopharmaceutical company developing Regenerative Macrophage Therapy (RMT) to treat inflammatory and fibrotic diseases, with an initial focus on end-stage liver disease. The company was founded in 2020 as a spinout from the University of Edinburgh's Centre for Regenerative Medicine, based on more than a decade of founders' research into the role of macrophages in organ repair. Its core technology is an ex vivo autologous cell therapy platform in which monocytes are collected from a patient's blood via leukapheresis, differentiated into pro-regenerative macrophages, engineered with therapeutic genes — including IL-10 (anti-inflammatory) and MMP9 (anti-fibrotic) — and re-infused intravenously. The lead product RTX001 is being evaluated in the open-label EMERALD Phase I/II study across 15 hepatology centers in the UK and Spain, enrolling up to 25 patients with decompensated cirrhosis; first patient was dosed in September 2025, with interim data expected in H2 2026.

The company's pipeline also includes an in vivo RMT program announced in June 2026, which uses proprietary mRNA payloads delivered via lipid nanoparticles to programme macrophages inside the body without ex vivo manufacturing, alongside preclinical-stage programs in graft-versus-host disease and lung fibrosis. Manufacturing is supported by academic and consortium partnerships: the Scottish National Blood Transfusion Service supplies GMP-grade macrophages, the University of Edinburgh provides licensed IP, CCRM/OmniaBio and panCELLa enable allogeneic iPSC-derived programs, and an Innovate UK-funded consortium with Cellular Origins and CGT Catapult is automating cell therapy manufacturing at Stevenage. The OPAL natural history study was set up in parallel to inform control-arm interpretation.

Resolution Therapeutics is privately held, registered in England and headquartered in London (245 Hammersmith Road) with R&D operations at the University of Edinburgh's Centre for Regenerative Medicine. It has raised approximately £100.1 million in disclosed funding — a £26.6m Series A (December 2020), a £10m Series A extension (April 2022) and a £63.5m Series B (October 2024) — entirely from Syncona Ltd, the London-listed life sciences investment firm. The commercial model is conventional biopharma product sales post-regulatory approval rather than current revenue generation; pricing is undisclosed. The company is led by CEO Amir Hefni (previously Global Head of Cell and Gene Therapy at Novartis), with Chairman Paul Sekhri (CEO of vTv Therapeutics; ex-eGenesis, Lycera, Novartis SVP BD&L) and a board that includes Syncona partners.

Short descriptiontext

Resolution Therapeutics is a clinical-stage biopharmaceutical company developing engineered Regenerative Macrophage Therapy (RMT), initially autologous RTX001 with IL-10/MMP9 for end-stage liver disease, targeting decompensated cirrhosis patients in the UK, Spain, the US and Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersEdinburgh, United Kingdom
HQ citystring
Edinburgh
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
macrophage cell therapy, regenerative macrophage therapy, engineered cell therapy, liver disease therapeutics, cell therapy manufacturing
Industry2 codes
PRIMARYHLAAABAF
Dendritic Cell & Other APC-based Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy Biopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Biopharmaceutical / Cell Therapy Revenue
TypeOne Time License
Description

Resolution Therapeutics is a clinical-stage biopharmaceutical company with no current revenue. The company is developing macrophage cell therapy products (RTX001 and in vivo RMT) targeting inflammatory and fibrotic diseases, with end-stage liver disease as the primary indication. Revenue is expected to be generated through product sales following regulatory approval, with potential for both autologous (personalized) and allogeneic (off-the-shelf) product offerings.

resolution-tx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Resolution Therapeutics is a clinical-stage biopharmaceutical company developing Regenerative Macrophage Therapy (RMT) for inflammatory and fibrotic diseases. Its lead asset RTX001 is an engineered autologous macrophage cell therapy enhanced with IL-10 and MMP9 therapeutic genes, currently in a Phase I/II EMERALD clinical trial for end-stage liver disease (decompensated cirrhosis). The company also operates a proprietary platform for macrophage differentiation, engineering, and cryopreserved manufacturing, and is developing a next-generation in vivo RMT program using mRNA delivered via lipid nanoparticles.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 70% transplant-free survival at 4 years vs 40% in control group (MATCH Phase 2, non-engineered macrophages)
+4 more records
Product overview1 text field

Resolution Therapeutics is a clinical-stage biopharmaceutical company pioneering Regenerative Macrophage Therapy (RMT) in inflammatory and fibrotic diseases. The company's product portfolio is anchored by its proprietary RMT platform, which underlies two therapeutic approaches: an ex vivo engineered autologous cell therapy (RTX001) and a next-generation in vivo program using mRNA delivered via lipid nanoparticles. Lead product RTX001 is an engineered autologous macrophage therapy enhanced with IL-10 and MMP9, currently in a Phase I/II EMERALD trial for end-stage liver disease. The company also operates the OPAL natural history study and is developing an in vivo RMT program. Prior clinical validation comes from the MATCH Phase 2 trial of non-engineered macrophages, which demonstrated 70% transplant-free survival at four years.

Product and service2 records
1RTX001
CategoryEngineered autologous macrophage cell therapy (lead clinical asset)
Description

RTX001 is Resolution Therapeutics' lead engineered autologous regenerative macrophage cell therapy, designed to deliver increased anti-fibrotic and anti-inflammatory effects in patients with end-stage liver disease. It is engineered ex vivo with a unique combination of therapeutic genes including IL-10 (anti-inflammatory) and MMP9 (anti-fibrotic/metalloprotease) to enhance the inherent regenerative properties of macrophages for superior efficacy and durability, representing a first-in-class potential treatment for decompensated liver cirrhosis.

2In Vivo Regenerative Macrophage Therapy (RMT) Program
CategoryIn vivo regenerative macrophage therapy (next-generation pipeline)
Description

Next-generation in vivo Regenerative Macrophage Therapy program that uses proprietary mRNA delivered via lipid nanoparticles (LNPs) to reprogram immune cells directly inside the patient, eliminating the need for cell collection or ex vivo manufacturing. The program complements Resolution's autologous RTX001 therapy and is intended to extend RMT to broader patient populations across inflammatory and fibrotic diseases.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-07-14
Description

Cellular Origins, Cell and Gene Therapy Catapult, and Resolution Therapeutics formed a consortium that won a £1m Innovate UK Smart Grant to develop a fully automated, scalable cell and gene therapy manufacturing platform. The 20-month project installs Cellular Origins' Constellation robotic system at CGT Catapult's Stevenage site. Resolution participates as a consortium partner providing therapeutic macrophage manufacturing use case. Additional support from ScaleReady (bioreactor) and Autolomous (electronic batch record platforms).

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-11-07
Description

Resolution Therapeutics signed a collaboration agreement with CCRM and its subsidiary OmniaBio Inc. to develop and scale up a manufacturing platform for Resolution's off-the-shelf iPSC-derived macrophage cell therapies. OmniaBio will leverage its technical expertise in iPSC differentiation, process development and GMP manufacturing to build a scalable manufacturing platform for Resolution's allogeneic macrophage programs.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-04-05
Description

Resolution Therapeutics entered a Research Evaluation and Option Agreement with panCELLa Inc. to develop iPSC-derived macrophage cell therapy for inflammatory organ disease. panCELLa provides its hypo-immunogenic engineered iPSC technology (FailSafe safety switch and iACT StealthCells for immune evasion) to support Resolution's allogeneic macrophage program. Resolution holds an option to obtain commercial rights to use the panCELLa technology in macrophage biology.

4University of Edinburgh / Edinburgh Innovations
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Resolution Therapeutics is a spinout from Professor Stuart Forbes' laboratory at the University of Edinburgh's Centre for Regenerative Medicine. The company was founded following a two-year research collaboration (2018-2020) with the University of Edinburgh. Resolution holds exclusive licensing rights to the macrophage cell therapy technology and data developed at the university. Susan Bodie (Head of Business Development, Edinburgh Innovations) serves as Board Observer.

resolution-tx.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Resolution partnered with SNBTS to optimise the macrophage manufacturing process and produce GMP-grade engineered macrophages for clinical use. SNBTS provided clinical macrophage material for the academic MATCH trial and continues as a manufacturing partner. Professor John Campbell, Director of Tissues, Cells & Advanced Therapeutics at SNBTS, is a co-founder of Resolution.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage cell therapy company developing allogeneic liver cell therapy for end-stage liver disease. Direct competitor in liver cell therapy with overlapping indication (decompensated cirrhosis) and similar autologous/allogeneic strategy overlap.

TypeDirect peer
Description

Cell therapy company developing liver-derived cell therapies for liver disease and urea cycle disorders. Direct peer in liver cell therapy targeting similar patient populations of advanced liver disease.

TypeDirect peer
Description

Clinical-stage biotechnology company developing cell therapy (CAP-1002, cardiosphere-derived cells) for inflammatory and fibrotic indications. Comparable in therapeutic modality (allogeneic cell therapy), inflammatory/fibrotic disease focus, and clinical-stage status.

TypeDirect peer
Description

Commercial-stage cell therapy company developing mesenchymal stem cell therapies for inflammatory diseases (e.g., remestemcel-L for GvHD). Highly comparable in cell therapy modality, inflammatory disease focus, and pipeline overlap in GvHD.

TypeBroad incumbent
Description

Commercial-stage biopharmaceutical company with approved resmetirom (Rezdiffra) for MASH/NASH. Comparable as a liver-focused biopharmaceutical competitor addressing the same underlying patient population as Resolution's end-stage liver program.

TypeBroad incumbent
Description

Large biopharmaceutical company with approved Casgevy (gene-edited cell therapy) and active cell/gene therapy pipeline including in vivo programs. Comparable as a large, well-capitalized cell/gene therapy player pursuing novel cell-based modalities.

TypeEmerging player
Description

Clinical-stage cell therapy company developing iPSC-derived natural killer (NK) cell and macrophage therapies for cancer and inflammatory diseases. Highly comparable in myeloid cell therapy platform focus and iPSC-derived macrophage strategy overlap.

TypeEmerging player
Description

Clinical-stage biotechnology company pioneering in vivo gene editing using LNP-delivered base editing technologies. Comparable to Resolution's in vivo RMT program in applying LNP-delivered nucleic acid payloads to program cells inside the body.

9bluebird bio
TypeBroad incumbent
Description

Cell and gene therapy company with commercialized autologous gene-modified cell therapies (e.g., Lyfgenia, Zynteglo). Comparable as an established cell therapy player with operational experience in autologous manufacturing and regulatory navigation.

10Pluristem Therapeutics
TypeEmerging player
Description

Cell therapy company developing placenta-derived allogeneic cell therapies for inflammatory and ischemic conditions. Comparable as a cell therapy company focused on inflammatory disease indications and manufacturing scale-up.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Resolution Therapeutics

Cell Therapy Biopharmaceuticalsresolution-tx.com

Resolution Therapeutics is a clinical-stage biopharmaceutical company developing engineered Regenerative Macrophage Therapy (RMT), initially autologous RTX001 with IL-10/MMP9 for end-stage liver disease, targeting decompensated cirrhosis patients in the UK, Spain, the US and Europe.

What Resolution Therapeutics does

Resolution Therapeutics Limited is a clinical-stage biopharmaceutical company developing Regenerative Macrophage Therapy (RMT) to treat inflammatory and fibrotic diseases, with an initial focus on end-stage liver disease. The company was founded in 2020 as a spinout from the University of Edinburgh's Centre for Regenerative Medicine, based on more than a decade of founders' research into the role of macrophages in organ repair. Its core technology is an ex vivo autologous cell therapy platform in which monocytes are collected from a patient's blood via leukapheresis, differentiated into pro-regenerative macrophages, engineered with therapeutic genes — including IL-10 (anti-inflammatory) and MMP9 (anti-fibrotic) — and re-infused intravenously. The lead product RTX001 is being evaluated in the open-label EMERALD Phase I/II study across 15 hepatology centers in the UK and Spain, enrolling up to 25 patients with decompensated cirrhosis; first patient was dosed in September 2025, with interim data expected in H2 2026.

The company's pipeline also includes an in vivo RMT program announced in June 2026, which uses proprietary mRNA payloads delivered via lipid nanoparticles to programme macrophages inside the body without ex vivo manufacturing, alongside preclinical-stage programs in graft-versus-host disease and lung fibrosis. Manufacturing is supported by academic and consortium partnerships: the Scottish National Blood Transfusion Service supplies GMP-grade macrophages, the University of Edinburgh provides licensed IP, CCRM/OmniaBio and panCELLa enable allogeneic iPSC-derived programs, and an Innovate UK-funded consortium with Cellular Origins and CGT Catapult is automating cell therapy manufacturing at Stevenage. The OPAL natural history study was set up in parallel to inform control-arm interpretation.

Resolution Therapeutics is privately held, registered in England and headquartered in London (245 Hammersmith Road) with R&D operations at the University of Edinburgh's Centre for Regenerative Medicine. It has raised approximately £100.1 million in disclosed funding — a £26.6m Series A (December 2020), a £10m Series A extension (April 2022) and a £63.5m Series B (October 2024) — entirely from Syncona Ltd, the London-listed life sciences investment firm. The commercial model is conventional biopharma product sales post-regulatory approval rather than current revenue generation; pricing is undisclosed. The company is led by CEO Amir Hefni (previously Global Head of Cell and Gene Therapy at Novartis), with Chairman Paul Sekhri (CEO of vTv Therapeutics; ex-eGenesis, Lycera, Novartis SVP BD&L) and a board that includes Syncona partners.

Resolution Therapeutics firmographics

Firmographics
Name
Resolution Therapeutics
Legal name
Resolution Therapeutics Limited
Website
https://resolution-tx.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
51–100 employees
Short description
Resolution Therapeutics is a clinical-stage biopharmaceutical company developing engineered Regenerative Macrophage Therapy (RMT), initially autologous RTX001 with IL-10/MMP9 for end-stage liver disease, targeting decompensated cirrhosis patients in the UK, Spain, the US and Europe.
Ownership category
akta.pro rank

Resolution Therapeutics industry classification

Industry
Product category
Cell Therapy Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAF
Dendritic Cell & Other APC-based Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Macrophage cell therapy
  • Regenerative macrophage therapy
  • Engineered cell therapy
  • Liver disease therapeutics
  • Cell therapy manufacturing

Where Resolution Therapeutics is headquartered

Location

Headquarters

HQ city
Edinburgh
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Resolution Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Biopharmaceutical / Cell Therapy Revenue: Resolution Therapeutics is a clinical-stage biopharmaceutical company with no current revenue. The company is developing macrophage cell therapy products (RTX001 and in vivo RMT) targeting inflammatory and fibrotic diseases, with end-stage liver disease as the primary indication. Revenue is expected to be generated through product sales following regulatory approval, with potential for both autologous (personalized) and allogeneic (off-the-shelf) product offerings.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Resolution Therapeutics product offering

Product offering

Core offering

Resolution Therapeutics is a clinical-stage biopharmaceutical company developing Regenerative Macrophage Therapy (RMT) for inflammatory and fibrotic diseases. Its lead asset RTX001 is an engineered autologous macrophage cell therapy enhanced with IL-10 and MMP9 therapeutic genes, currently in a Phase I/II EMERALD clinical trial for end-stage liver disease (decompensated cirrhosis). The company also operates a proprietary platform for macrophage differentiation, engineering, and cryopreserved manufacturing, and is developing a next-generation in vivo RMT program using mRNA delivered via lipid nanoparticles.

Product overview

Resolution Therapeutics is a clinical-stage biopharmaceutical company pioneering Regenerative Macrophage Therapy (RMT) in inflammatory and fibrotic diseases. The company's product portfolio is anchored by its proprietary RMT platform, which underlies two therapeutic approaches: an ex vivo engineered autologous cell therapy (RTX001) and a next-generation in vivo program using mRNA delivered via lipid nanoparticles. Lead product RTX001 is an engineered autologous macrophage therapy enhanced with IL-10 and MMP9, currently in a Phase I/II EMERALD trial for end-stage liver disease. The company also operates the OPAL natural history study and is developing an in vivo RMT program. Prior clinical validation comes from the MATCH Phase 2 trial of non-engineered macrophages, which demonstrated 70% transplant-free survival at four years.

Differentiator

Problem solved

Functional benefit

Products and services

  • RTX001 RTX001 is Resolution Therapeutics' lead engineered autologous regenerative macrophage cell therapy, designed to deliver increased anti-fibrotic and anti-inflammatory effects in patients with end-stage liver disease. It is engineered ex vivo with a unique combination of therapeutic genes including IL-10 (anti-inflammatory) and MMP9 (anti-fibrotic/metalloprotease) to enhance the inherent regenerative properties of macrophages for superior efficacy and durability, representing a first-in-class potential treatment for decompensated liver cirrhosis.
  • In Vivo Regenerative Macrophage Therapy (RMT) Program Next-generation in vivo Regenerative Macrophage Therapy program that uses proprietary mRNA delivered via lipid nanoparticles (LNPs) to reprogram immune cells directly inside the patient, eliminating the need for cell collection or ex vivo manufacturing. The program complements Resolution's autologous RTX001 therapy and is intended to extend RMT to broader patient populations across inflammatory and fibrotic diseases.

Quantifiable outcome

  • 70% transplant-free survival at 4 years vs 40% in control group (MATCH Phase 2, non-engineered macrophages)
  • +4 more outcomes

Companies that use Resolution Therapeutics

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Resolution Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Resolution Therapeutics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor and core.

  • Cellular OriginsminorStrategic or Co-development Partner · 14 July 2025Cellular Origins, Cell and Gene Therapy Catapult, and Resolution Therapeutics formed a consortium that won a £1m Innovate UK Smart Grant to develop a fully automated, scalable cell and gene therapy manufacturing platform. The 20-month project installs Cellular Origins' Constellation robotic system at CGT Catapult's Stevenage site. Resolution participates as a consortium partner providing therapeutic macrophage manufacturing use case. Additional support from ScaleReady (bioreactor) and Autolomous (electronic batch record platforms).
  • CCRM / OmniaBio Inc.minorStrategic or Co-development Partner · 7 November 2022Resolution Therapeutics signed a collaboration agreement with CCRM and its subsidiary OmniaBio Inc. to develop and scale up a manufacturing platform for Resolution's off-the-shelf iPSC-derived macrophage cell therapies. OmniaBio will leverage its technical expertise in iPSC differentiation, process development and GMP manufacturing to build a scalable manufacturing platform for Resolution's allogeneic macrophage programs.
  • panCELLa Inc.minorStrategic or Co-development Partner · 5 April 2022Resolution Therapeutics entered a Research Evaluation and Option Agreement with panCELLa Inc. to develop iPSC-derived macrophage cell therapy for inflammatory organ disease. panCELLa provides its hypo-immunogenic engineered iPSC technology (FailSafe safety switch and iACT StealthCells for immune evasion) to support Resolution's allogeneic macrophage program. Resolution holds an option to obtain commercial rights to use the panCELLa technology in macrophage biology.
  • University of Edinburgh / Edinburgh InnovationscoreStrategic or Co-development PartnerResolution Therapeutics is a spinout from Professor Stuart Forbes' laboratory at the University of Edinburgh's Centre for Regenerative Medicine. The company was founded following a two-year research collaboration (2018-2020) with the University of Edinburgh. Resolution holds exclusive licensing rights to the macrophage cell therapy technology and data developed at the university. Susan Bodie (Head of Business Development, Edinburgh Innovations) serves as Board Observer.
  • Scottish National Blood Transfusion Service (SNBTS)minorStrategic or Co-development PartnerResolution partnered with SNBTS to optimise the macrophage manufacturing process and produce GMP-grade engineered macrophages for clinical use. SNBTS provided clinical macrophage material for the academic MATCH trial and continues as a manufacturing partner. Professor John Campbell, Director of Tissues, Cells & Advanced Therapeutics at SNBTS, is a co-founder of Resolution.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Resolution Therapeutics competitors and assessment

Company assessment

Direct peers

  • Lygenesis: Clinical-stage cell therapy company developing allogeneic liver cell therapy for end-stage liver disease. Direct competitor in liver cell therapy with overlapping indication (decompensated cirrhosis) and similar autologous/allogeneic strategy overlap.
  • HepaTx (formerly Promethera Biosciences): Cell therapy company developing liver-derived cell therapies for liver disease and urea cycle disorders. Direct peer in liver cell therapy targeting similar patient populations of advanced liver disease.
  • Capricor Therapeutics: Clinical-stage biotechnology company developing cell therapy (CAP-1002, cardiosphere-derived cells) for inflammatory and fibrotic indications. Comparable in therapeutic modality (allogeneic cell therapy), inflammatory/fibrotic disease focus, and clinical-stage status.
  • Mesoblast: Commercial-stage cell therapy company developing mesenchymal stem cell therapies for inflammatory diseases (e.g., remestemcel-L for GvHD). Highly comparable in cell therapy modality, inflammatory disease focus, and pipeline overlap in GvHD.

Broad incumbents

  • Madrigal Pharmaceuticals: Commercial-stage biopharmaceutical company with approved resmetirom (Rezdiffra) for MASH/NASH. Comparable as a liver-focused biopharmaceutical competitor addressing the same underlying patient population as Resolution's end-stage liver program.
  • Vertex Pharmaceuticals: Large biopharmaceutical company with approved Casgevy (gene-edited cell therapy) and active cell/gene therapy pipeline including in vivo programs. Comparable as a large, well-capitalized cell/gene therapy player pursuing novel cell-based modalities.
  • bluebird bio: Cell and gene therapy company with commercialized autologous gene-modified cell therapies (e.g., Lyfgenia, Zynteglo). Comparable as an established cell therapy player with operational experience in autologous manufacturing and regulatory navigation.

Emerging players

  • Shoreline Biosciences: Clinical-stage cell therapy company developing iPSC-derived natural killer (NK) cell and macrophage therapies for cancer and inflammatory diseases. Highly comparable in myeloid cell therapy platform focus and iPSC-derived macrophage strategy overlap.
  • Verve Therapeutics: Clinical-stage biotechnology company pioneering in vivo gene editing using LNP-delivered base editing technologies. Comparable to Resolution's in vivo RMT program in applying LNP-delivered nucleic acid payloads to program cells inside the body.
  • Pluristem Therapeutics: Cell therapy company developing placenta-derived allogeneic cell therapies for inflammatory and ischemic conditions. Comparable as a cell therapy company focused on inflammatory disease indications and manufacturing scale-up.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Resolution Therapeutics social profiles

Digital presence

Resolution Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Resolution Therapeutics leadership team

Management profile

Number of profiles

Profiles17 records

Resolution Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Resolution Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Resolution Therapeutics

What does Resolution Therapeutics do?

Resolution Therapeutics is a clinical-stage biopharmaceutical company developing Regenerative Macrophage Therapy (RMT) for inflammatory and fibrotic diseases. Its lead asset RTX001 is an engineered autologous macrophage cell therapy enhanced with IL-10 and MMP9 therapeutic genes, currently in a Phase I/II EMERALD clinical trial for end-stage liver disease (decompensated cirrhosis). The company also operates a proprietary platform for macrophage differentiation, engineering, and cryopreserved manufacturing, and is developing a next-generation in vivo RMT program using mRNA delivered via lipid nanoparticles.

Is Resolution Therapeutics a public or private company?

Resolution Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Resolution Therapeutics founded?

Resolution Therapeutics was founded in 2020. It employs 51 to 100 people.

Where is Resolution Therapeutics based?

Resolution Therapeutics is headquartered in Edinburgh, United Kingdom, in the Europe region.

How does Resolution Therapeutics make money?

One revenue line is on record: biopharmaceutical / Cell Therapy Revenue.

Who are Resolution Therapeutics's main competitors?

Direct peers on record are Lygenesis, HepaTx (formerly Promethera Biosciences), Capricor Therapeutics and Mesoblast. Broad incumbents are Madrigal Pharmaceuticals, Vertex Pharmaceuticals and bluebird bio. Emerging players are Shoreline Biosciences, Verve Therapeutics and Pluristem Therapeutics.

Does Resolution Therapeutics have an API?

No public API is recorded for Resolution Therapeutics.

What industry is Resolution Therapeutics in?

Resolution Therapeutics's product category is Cell Therapy Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAF, Dendritic Cell & Other APC-based Therapies, with a secondary code of HLAAAGAL, Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyResolution’s engineered immune cells show early liver promiseResolution Therapeutics shared an interim readout of RTX001, an engineered immune cell therapy, in end-stage liver disease. The data suggest the drug may cut deaths, transplants, and decompensation, but the nine-patient sample is small and the company calls it a signal of efficacy.Longevity.TechnologyResolution Therapeutics posts positive interim EMERALD resultsResolution Therapeutics reported positive interim six-month results from its Phase I/II EMERALD trial of RTX001 in end-stage liver disease, showing a 42% relative risk reduction in the composite endpoint of death, transplant, or decompensation. The company plans a pre-IND meeting with the FDA in December 2026 and intends to advance RTX001 toward a U.S. pivotal trial.MarketScreenerSyncona investee Resolution gets good results from liver disease trialResolution Therapeutics reported positive interim data from its phase I/II Emerald trial of RTX001, a cell therapy for end-stage liver disease, with six-month results showing improvements and reduced inflammation biomarkers. The company plans to advance the therapy into a pivotal study, with a US FDA meeting scheduled for December 2026. Syncona, which holds an 82.8% stake, said the results support future valuation growth.Longevity.TechnologyResolution Therapeutics to present interim liver disease therapy data at AASLDResolution Therapeutics will present interim data from its Phase I/II EMERALD study of RTX001 at the AASLD meeting in Denver, Nov 5-9, 2026. The study evaluates the engineered Regenerative Macrophage Therapy in patients with end-stage liver disease who recovered from recent hepatic decompensation. The poster session is scheduled for Sunday, 8 Nov 2026.Longevity.TechnologyLiver disease trial finishes dosing all patientsResolution Therapeutics completed dosing the final patient in its EMERALD Phase I/II trial of RTX001, an engineered macrophage therapy for end-stage liver disease. Fifteen patients were treated, with interim data expected in Q4 2026. The company plans a pivotal US study in 2027.Longevity.TechnologyCell therapy for liver failure eyes hometown accessResolution Therapeutics partnered with Blood Centers of America to deliver its cell therapy RTX001 for end-stage liver disease in community settings. The therapy reprograms macrophages to promote liver regeneration and is designed for repeat-dose IV administration. A pivotal US trial is planned for 2027.Longevity.TechnologyResolution’s cell therapy trial for severe liver disease completes enrollmentResolution Therapeutics completed enrollment in its Phase I/II EMERALD trial of RTX001 for end-stage liver disease, with 15 patients dosed. The engineered macrophage therapy is given via a short IV infusion without pre-conditioning. The company expects interim data in Q4 2026 and a pivotal U.S. study in 2027.BioSpaceResolution Therapeutics completes enrollment in Phase I/II EMERALD clinical trial evaluating RTX001 in end-stage liver diseaseResolution Therapeutics completed enrollment in its Phase I/II EMERALD trial of RTX001 for end-stage liver disease, with 15 patients dosed. Interim data are expected in Q4 2026, and the company plans a pivotal U.S. study in 2027.Longevity.TechnologyResolution Therapeutics, BCA partner to expand access to experimental liver disease therapyResolution Therapeutics partnered with Blood Centers of America to expand U.S. access to RTX001, its experimental liver disease therapy. The partnership makes BCA a preferred provider for cell collection and processing, aiming to enable treatment in community settings. A pivotal study is planned for 2027 after a pre-IND meeting with the FDA.PharmafileCell therapy partnership aims to bring liver disease treatment closer to US patientsResolution Therapeutics partnered with Blood Centers of America to support community-based delivery of its experimental cell therapy RTX001 for end-stage liver disease. The pivotal clinical programme is planned to begin in the US in 2027, aiming to widen access for patients facing travel barriers. The company will finalize study design and site selection after an FDA IND meeting.